Pulse Biosciences, Inc. (NASDAQ:PLSE) Director Buys $949,298.08 in Stock

Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) Director Robert W. Duggan acquired 55,256 shares of the firm's stock in a transaction that occurred on Friday, December 13th. The shares were purchased at an average price of $17.18 per share, with a total value of $949,298.08. Following the acquisition, the director now owns 42,328,717 shares of the company's stock, valued at approximately $727,207,358.06. This trade represents a 0.13 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pulse Biosciences Stock Performance

PLSE stock traded up $0.07 during midday trading on Tuesday, hitting $19.24. 157,588 shares of the company's stock were exchanged, compared to its average volume of 201,113. Pulse Biosciences, Inc. has a one year low of $6.59 and a one year high of $22.69. The stock's fifty day moving average price is $17.74 and its 200-day moving average price is $16.50.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter last year, the company posted ($0.19) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD acquired a new stake in shares of Pulse Biosciences in the first quarter valued at approximately $88,000. Cetera Advisors LLC bought a new position in shares of Pulse Biosciences in the 1st quarter valued at about $109,000. Bank of New York Mellon Corp increased its position in shares of Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company's stock valued at $570,000 after acquiring an additional 9,639 shares during the last quarter. Rhumbline Advisers increased its position in shares of Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company's stock valued at $288,000 after acquiring an additional 1,608 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in Pulse Biosciences during the second quarter worth about $91,000. Institutional investors own 76.95% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Pulse Biosciences to a "sell" rating in a research report on Thursday, December 12th.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.